Linezolid B. Braun (Linezolid)

Linezolid exerts its antibacterial effect by binding to the 50S subunit of bacterial ribosomes. This binding prevents the formation of the initiation complex needed for protein synthesis, halting the production of essential proteins and leading to bacterial growth inhibition and cell death, particularly against Gram‑positive pathogens.

The specific dose and duration of linezolid therapy are determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and other clinical factors. Healthcare professionals should follow local guidelines and product labeling when establishing the appropriate regimen.

Data on linezolid use during pregnancy and lactation are limited. The drug should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should discuss potential risks and consider alternative therapies when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including cold‑chain if needed), and required import documentation.

Linezolid offers oral and intravenous options with excellent activity against resistant Gram‑positive bacteria, whereas vancomycin, a glycopeptide, is limited to intravenous use and may have nephrotoxicity concerns. Linezolid also penetrates lung tissue well, making it advantageous for pneumonia, but it requires monitoring for hematologic toxicity.

Linezolid B. Braun should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the solution from light, moisture, and extreme temperatures. Do not freeze. Once reconstituted, use according to the manufacturer’s stability guidelines and discard any unused portion after the recommended time.

Linezolid B. Braun is administered by intravenous infusion. The infusion should be given over a period recommended by the prescribing information, typically over 30–60 minutes, using aseptic technique. Healthcare professionals must ensure proper dilution and compatibility with the chosen infusion fluid before administration.

Serious adverse events include thrombocytopenia, peripheral neuropathy, optic neuritis, serotonin syndrome (especially with serotonergic drugs), myelosuppression, and lactic acidosis. Patients should be monitored regularly for blood‑cell abnormalities, visual changes, neuropathic symptoms, and signs of metabolic disturbance throughout therapy.

Linezolid is contraindicated in individuals with known hypersensitivity to linezolid or any component of the formulation. It should also be avoided in patients currently receiving monoamine oxidase inhibitors (MAOIs) and used with caution in those taking serotonergic agents due to the risk of serotonin syndrome. Clinicians must assess each patient’s medical history before initiating therapy.